{"id":46524,"date":"2022-07-25T16:03:06","date_gmt":"2022-07-25T14:03:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-expands-ready-to-administer-portfolio-with-glycopyrrolate-injection-usp-simplist-prefilled-syringe\/"},"modified":"2022-07-25T16:03:06","modified_gmt":"2022-07-25T14:03:06","slug":"fresenius-kabi-expands-ready-to-administer-portfolio-with-glycopyrrolate-injection-usp-simplist-prefilled-syringe","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fresenius-kabi-expands-ready-to-administer-portfolio-with-glycopyrrolate-injection-usp-simplist-prefilled-syringe\/","title":{"rendered":"Fresenius Kabi Expands Ready-to-Administer Portfolio with Glycopyrrolate Injection, USP Simplist\u00ae Prefilled Syringe"},"content":{"rendered":"
\n

\nReducing preparation steps to help support patient safety<\/b>\n<\/p>\n

LAKE ZURICH, Ill.–(BUSINESS WIRE)–#FreseniusKabi<\/a>–Fresenius Kabi announced today the immediate availability in the U.S. of Glycopyrrolate Injection, USP in 0.6 mg per 3 mL Simplist\u00ae <\/sup>ready-to-administer prefilled syringes<\/a>.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nFresenius Kabi Simplist Glycopyrrolate Injection, USP is the most recent manufacturer-prepared product available in the company\u2019s proprietary, ready-to-administer portfolio of Simplist prefilled syringes, which reduce the amount of time nurses spend preparing doses and documenting waste.1<\/sup>\n<\/p>\n

\n\u201cFresenius Kabi is focused on helping reduce clinician burden by expanding our ready-to-administer offerings,\u201d said John Ducker, president and CEO of Fresenius Kabi USA. \u201cWe\u2019re pleased that our Simplist prefilled syringe portfolio now includes Glycopyrrolate Injection, USP, which will minimize preparation complexity to streamline workflows and help support patient safety in the U.S.\u201d\n<\/p>\n

\nFresenius Kabi Glycopyrrolate Injection, USP 0.6 mg per 3 mL Simplist prefilled syringe may be administered prior to or concomitantly with Simplist Neostigmine Methylsulfate Injection, USP 3 mg per 3 mL prefilled syringe for reversal of neuromuscular blockade. See package inserts for complete dosage and administration information at www.simplist-us.com<\/a>. Fresenius Kabi also offers Glycopyrrolate Injection, USP in vials.\n<\/p>\n

\nFresenius Kabi continues to invest in expanding its suite of ready-to-administer (RTA) offerings to assure pharmacists and nurses have a wide range of prefilled, standard strengths, single-patient delivery systems options \u2014 from bags to syringes \u2014 that streamline medication management from the pharmacy to the bedside, eliminating steps where errors can occur.\n<\/p>\n

\nFresenius Kabi Simplist Glycopyrrolate Injection, USP is formulated, filled and packaged in the U.S., and is the newest example of the company\u2019s commitment to investing \u201cMore in America<\/a>.\u201d This effort is focused on providing more supply, more science, more support and more care to its customers and the patients they serve in the U.S. Fresenius Kabi has invested nearly $1 billion to modernize and expand advanced U.S. pharmaceutical production and distribution facilities.\n<\/p>\n

\nTo learn more about the Simplist portfolio with pharmacy clinical education support, please visit www.simplist-us.com<\/a>.\n<\/p>\n

\nINDICATIONS AND USAGE<\/b>\n<\/p>\n

\nGlycopyrrolate Injection, for intramuscular or intravenous use, is an anticholinergic indicated:\n<\/p>\n

\nin anesthesia (adult and pediatric patients)\n<\/p>\n